• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>China Distance Education Holdings Limited ADR

China Distance Education Holdings Limited ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Turkey’s Leading University Hospital Adopts Masimo SpHb for Continuous Noninvasive Haemoglobin Monitoring

    Turkey’s Leading University Hospital Adopts Masimo SpHb for Continuous Noninvasive Haemoglobin Monitoring

  2. Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

    Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

  3. Cheeseburger Bobby’s Introduces Millennial-Focused Design Prototype

    Cheeseburger Bobby’s Introduces Millennial-Focused Design Prototype

  4. China Mobile Partners ZTE and Qualcomm on 3-Carrier Aggregation Trial

    China Mobile Partners ZTE and Qualcomm on 3-Carrier Aggregation Trial

  5. bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA

    bluebird bio Reports New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA

  6. Study: Once-Weekly Trulicity™ (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks

    Study: Once-Weekly Trulicity™ (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks

  7. Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine

    Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine

  8. Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA

    Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA

  9. Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial

    Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial

  10. Lexicon Announces Presentation Of Manuscript At The American Diabetes Association Diabetes Care Symposium

    Lexicon Announces Presentation Of Manuscript At The American Diabetes Association Diabetes Care Symposium

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.